SG Americas Securities LLC Increases Stock Holdings in uniQure N.V. $QURE

SG Americas Securities LLC grew its position in shares of uniQure N.V. (NASDAQ:QURE) by 1,107.3% during the first quarter, HoldingsChannel reports. The firm owned 776,604 shares of the biotechnology company’s stock after buying an additional 712,278 shares during the period. SG Americas Securities LLC’s holdings in uniQure were worth $12,697,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Torren Management LLC purchased a new stake in uniQure during the 4th quarter worth approximately $28,000. IFP Advisors Inc acquired a new stake in shares of uniQure during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $48,000. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the third quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after buying an additional 906 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling at uniQure

In other uniQure news, Director David D. Meek sold 1,993 shares of uniQure stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the transaction, the director directly owned 39,747 shares in the company, valued at $1,075,553.82. The trade was a 4.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 359,546 shares of company stock worth $14,549,943. 4.65% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on QURE shares. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research note on Wednesday, June 17th. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $25.00 to $65.00 in a research note on Thursday, June 18th. Finally, Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday, May 5th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.67.

uniQure Stock Performance

Shares of QURE opened at $47.51 on Friday. The stock has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. The business’s fifty day moving average price is $27.84 and its 200 day moving average price is $23.02. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.